WO2008140419A2 - Dérivés de pyrimidine à substitution pyridyle - Google Patents

Dérivés de pyrimidine à substitution pyridyle Download PDF

Info

Publication number
WO2008140419A2
WO2008140419A2 PCT/SG2008/000178 SG2008000178W WO2008140419A2 WO 2008140419 A2 WO2008140419 A2 WO 2008140419A2 SG 2008000178 W SG2008000178 W SG 2008000178W WO 2008140419 A2 WO2008140419 A2 WO 2008140419A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
disease
optionally substituted
syndrome
leukaemia
Prior art date
Application number
PCT/SG2008/000178
Other languages
English (en)
Other versions
WO2008140419A3 (fr
Inventor
Dizhong Chen
Cheng Hsia Angeline Lee
Harish Kumar Mysore Nagaraj
Anders Poulsen
Anthony Deodaunia William
Original Assignee
S*Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S*Bio Pte Ltd filed Critical S*Bio Pte Ltd
Publication of WO2008140419A2 publication Critical patent/WO2008140419A2/fr
Publication of WO2008140419A3 publication Critical patent/WO2008140419A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention relates to pyrimidine compounds that may be useful as agents for targeting kinase related disorders. More particularly, the present invention relates to pyridyl substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of kinase related disorders such as proliferative disorders. These compounds may therefore be useful as medicaments for the treatment of a number of kinase related disorders such as proliferative disorders including tumours and cancers as well as other conditions or disorders associated with kinases.
  • Proliferative disorders such as cancer are characterised by the uncontrolled growth of cells within the body. As such proliferative disorders generally involve an abnormality in the control of cell growth and/or division leading to the formation of tumour and ultimately death. Without wishing to be bound by theory it is thought that this is caused by the pathways that regulate cell growth and division being altered in cancer cells. The alteration is such that the effects of these normal regulatory mechanisms in controlling cell growth and division either fails or is bypassed.
  • the uncontrolled cell growth and/or division ultimately proves fatal for the patient as successive rounds of mutations on the part of the cell then typically lead to the cancer cells having a selective advantage over normal healthy cells in the body of the patient leading to the cancer cells predominating in the cell mass of the patient.
  • the cancer cells then typically metastasize to colonize other tissues or parts of the body other than the part of origin of the cancer cell leading to secondary tumours. These secondary tumours eventually lead to organ failure and the death of the patient. It is the difficulty in controlling the rapid cell growth and division that is characteristic of cancer cells that make it hard to come up with effective chemotherapeutic strategies.
  • Treatments that have been utilised include ionizing radiation ( ⁇ -rays, X-rays and the like) as well as cytotoxic agents such as bleomycin, cis-platin, vinblastine, cyclophosphamide, 5'-fluorouracil and methotrexate. These treatments all rely on causing damage to DNA and destabilisation of the chromosomal structure eventually leading to death of the cancer cells.
  • a difficulty with many of these approaches is that they are non-selective for cancer cells and healthy cells can and often will be adversely affected by the treatment. This is hardly surprising given that the cellular mechanisms targeted by these strategies occur in healthy cells as well as in cancer cells (although typically at slower rates in the healthy cells) and this highlights the difficulty in achieving successful treatment of the cancer in the patient without causing irreparable harm to the healthy cells. As such with many of these treatments there can be devastating side effects which can not only significantly reduce the short term quality of life of the patient but may also have long term detriments on the health of the patient should they survive the cancer attack.
  • combination therapies typically involve the use of anti- cancer drugs with different properties and cellular targets which in turn tends to increase the overall effectiveness of any chosen chemotherapy regime and limits the possibility of drug resistance developing in the patient.
  • Small-molecule kinase inhibitors that are now approved for oncology indications include imatinib, gefitinib, erlotinib, sorafenib, sunitinib and dasatinib [Baselga J., Science, 2006, 312, 1175-1178].
  • a number of kinases such as JAK2, FLT3 and CDK2 are promising kinase targets for pharmacological intervention in solid tumours, hematological malignancies, myeloproliferative disorders and non-malignant proliferative disorders like keloids.
  • the Janus kinases are a family of cytoplasmic tyrosine kinases consisting of JAK1, JAK2, JAK3 and Tyk2. They play a pivotal role in the signaling pathways of numerous cytokines, hormones and growth factors [Rawlings JS et al, J. Cell ScL, 2004, 117, 1281-1283]. Their intracellular substrates include the family of proteins called Signal Transducer and Activator of Transcription (STAT). The JAK-STAT pathways, through the proper actions of the ligands, regulate important physiological processes such as immune response to viruses, erythropoiesis, lactation, lipid homeostasis, etc.
  • STAT Signal Transducer and Activator of Transcription
  • JAK2 myeloproliferative disorders
  • myeloproliferative disorders including polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis
  • myeloproliferative disorders belong to an area of unmet medical need where some treatment modalities have not been updated over the past few decades [Schafer Al, Blood, 2006, 107, 4214-4222].].
  • the myeloproliferative disorders belong to a group of haematological malignancies arising from clonal expansion of mutated progenitor stem cells in the bone marrow.
  • the association of one MPD, chronic myeloid leukaemia, with the Philadelphia chromosome has been well documented.
  • the Philadelphia negative MPDs include Essential Thrombocythemia (ET), Polycythemia Vera (PV) and Chronic Idiopathic Myelofibrosis (MF). No effective treatment is currently available.
  • JAK2 Essential Thrombocythemia
  • PV Polycythemia Vera
  • MF Chronic Idiopathic Myelofibrosis
  • Essential Thrombocythemia is a chronic MPD characterized by an increased number of circulating platelets, profound marrow megakaryocyte hyperplasia, splenomegaly and a clinical course punctuated by hemorrhagic or thrombotic episodes or both.
  • Current treatment options include low dose aspirin, or platelet lowering agents such as anagrelide, interferon or hydroxyurea. These treatments have severe side effects that compromise the quality of life of patients.
  • Polycythemia Vera is a chronic progressive MPD characterized by an elevated hematocrit, an increase in the red cell mass, and usually by an elevated leukocyte count, an elevated platelet count and an enlarged spleen.
  • Treatment options include: phlebotomy with low dose aspirin or myelosuppressive therapy options such as hydroxyurea, interferon or anagrelide. Again, these treatments are not ideal due to severe side effects.
  • Chronic Idiopathic Myelofibrosis is a chronic malignant hematological disorder characterized by an enlarged spleen, varying degrees of anemia and low platelet counts, red cells in the peripheral blood that resemble tear drops, the appearance of small numbers of immature nucleated red cells and white cells in the blood, varying degrees of fibrosis of the marrow cavity (myelofibrosis) and the presence of marrow cells outside the marrow cavity (extramedullar/ hematopoiesis or myeloid metaplasia).
  • Current treatment is directed at alleviation of constitutional symptoms, anemia and symptomatic splenomegaly.
  • Treatment options include hydroxyurea, interferon, thalidomide with prednisone, and allogeneic stem cell transplant.
  • MF has the worst prognosis among the Philadelphia negative MPD and represents an area of greatest unmet medical need.
  • JAK2 is also implicated in the etiology of cardiovascular diseases like congestive heart failure and pulmonary hypertension [Berk BC et al, Circ. Res, 1997, 80, 607-616]. Furthermore, a putative role for JAK2 has been demonstrated in keloid pathogenesis and may constitute a new approach for keloid management [Lim CP et al, Oncogene, 2006, 25, 5416-5425].
  • JAK2 inhibitors lie in the treatment of retinal diseases as JAK2 inhibition was found to offer protective effects on photoreceptors in a mouse model of retinal degeneration [Samardzija M et al, FASEB J., 2006, 10, 1096].
  • RTK Class III receptor tyrosine kinases
  • FLT3 fms- like receptor tyrosine kinase 3
  • platelet-derived growth factor receptors c-Fms, c-Kit, fms- like receptor tyrosine kinase 3 (FLT3), and platelet-derived growth factor receptors
  • PDGFR ⁇ and ⁇ play an important role in the maintenance, growth and development of hematopoietic and non-hematopoietic cells.
  • Over expression and activating mutations of these RTKs are known to be involved in the pathophysiology of diverse human cancers from both solid and hematological origins [Hannah AL, Curr. MoI. Med., 2005, 5, 625-642].
  • FLT3 mutations were first reported as internal tandem duplication (FLT3/ITD) of the juxtamembrane domain-coding sequence; subsequently, point mutations, deletions, and insertions surrounding the D835 coding sequence have been found [Parcells BW et al, Stem Cells, 2006, 24, 1174-1184].
  • FLT3 mutations are the most frequent genetic alterations reported in acute myeloid leukemia (AML) and are involved in the signaling pathway of autonomous proliferation and differentiation block in leukemia cells [Tickenbrock L et al, Expert Opin. Emerging Drugs, 2006, 11, 1-13].
  • AML acute myeloid leukemia
  • FLT3/ITD is strongly associated with a poor prognosis. Because high-dose chemotherapy and stem cell transplantation cannot overcome the adverse effects of FLT3 mutations, the development of FLT3 kinase inhibitors could produce a more efficacious therapeutic strategy for leukemia therapy.
  • Cyclin-dependent kinases are serine-threonine kinases that play important roles in cell cycle control (CDK1 , 2, 4 and 6), transcription initiation (CDK7 and 9), and neuronal function (CDK5) [Knockaert M et al, Trends Pharmacol. ScL, 2002, 23, 417-425]. Aberrations in the cell cycle CDKs and their cyclin partners have been observed in various tumour types, including those of the breast, colon, liver and brain [Shapiro Gl 1 J. CHn. Oncol., 2006, 24, 1770-1783]. It is believed that the pharmacological inhibition of CDK1, 2, 4, 6 and/or 9 may provide a new therapeutic option for diverse cancer patients.
  • JAK2 for example is involved in numerous interleukin signaling pathways which may render it a suitable target for seeking new treatment modalities for inflammatory disorders including asthma, psoriasis, and rheumatoid arthritis [Leonard WJ, Int. J. Haematol., 2001, 73, 271].
  • Inflammation for example, is a natural biological response to microbial challenge and other forms of threats or breach of tissue integrity. It is characterized by increased vascular permeability accompanied by an infiltration of specialized blood cells (neutrophils, macrophages, lymphocytes and plasma cells) into the inflamed area. These cellular responses are mediated by the appearance of adhesion molecules on endothelia and the release of inflammatory mediators (cytokines and prostaglandins) from tissue cells and leukocytes. The cardinal signs of inflammation are pain, edema, redness and warmth at the affected site. When occurring in a self-limiting fashion within the context of bona fide foreign insults, inflammation is a physiological process that puts the tissues on the path to recovery and prevents further damage.
  • inflammatory mediators cytokines and prostaglandins
  • autoimmune diseases which are pathological states caused by the body producing an inappropriate immune response against its own tissues.
  • the immune system ceases to recognize one or more of the body's normal constituents as "self and generates auto-antibodies - antibodies that attack its own cells, tissues, and/or organs. This results in inflammation and ' other concomitant damage which together constitute the symptoms of autoimmune diseases.
  • kinase targets that have been identified as being involved in a number of disorders and compounds that target these kinases should display interesting biological activity.
  • compounds that are kinase inhibitors have the potential to meet the need to provide further biologically active compounds that would be expected to have useful, improved pharmaceutical properties in the treatment of kinase related conditions or disorders such as cancer and other proliferative disorders.
  • the compounds developed be able to provide activity against more than one kinase as in many instances multi-faceted activity allows the compound to attack the disorder in a number of different ways/pathways.
  • the compound display JAK2 activity as this kinase is associated with a number of disorders as discussed above.
  • the compound be a CDK inhibitor as cyclin dependent kinases are also found to be involved in a number of disorders.
  • the present applicants have identified a family of pyridyl substituted pyrimidines which show activity against JAK2 as well as being inhibitors of cyclin dependent kinases (such as CDK2) and have promising drug like properties.
  • the compounds are thus very promising candidates for the treatment of kinase related conditions.
  • the present invention provides a compound of formula (I):
  • R 1 is selected from the group consisting of: H, halogen, OH 1 OCH 3 , OCF 3 , OCH 2 CH 3 , NO 2 , NH 2 , NHCH 3 , NHCH 2 CH 3 , N(CH 3 ) 2 , SH, SCH 3, optionally substituted C 1 - C 4 alkoxy, and optionally substituted C r C 4 alkyl;
  • each R 2 is independently selected from the group consisting of H, halogen, OH, NO 2 , CN, NH 2 , optionally substituted C r C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted d-C ⁇ heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted Ci-Ci 2 heterocycloalkyl, optionally substituted d-C ⁇ alkyloxy, optionally substituted C r Cioheteroalkyloxy, optionally substituted C r C 12 alkylamino, SR 4 , SO 3 H, SO 2 NH 2 , SO 2 R 4 , SONH 2 , SOR 4 , COR 4 , COOH, COOR 4 , CONHR 4 , NHCOR 4 , NHCOOR 4 , NHSO 2 R 4 , NHCONHR 4 , NR 4 R
  • each R 4 and R 5 is independently selected from the group consisting of H, optionally substituted Ci-C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted CrC 10 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted C 1 -C 12 heterocycloalkyl, optionally substituted CrC 12 heterocycloalkenyl, optionally substituted C 6 - C 18 aryl, and optionally substituted Ci-C 18 heteroaryl;
  • n is an integer selected from the group consisting of O, 1 , 2, and 3;
  • n is an integer selected from the group consisting of O, 1 , 2, 3, and 4;
  • L is a group of formula:
  • X 1 is attached to the pyridyl moiety and X 2 is attached to the phenyl moiety, and wherein X 1 , X 2 and Y are selected such that the group L has between 5 and 15 atoms in the normal chain,
  • X 1 and X 2 are each independently a heteroalkyl group containing at least one oxygen atom in the normal chain
  • X 1 , X 2 and Y are chosen such that there are between 5 and 15 atoms in the normal chain. In one embodiment of the compounds of the invention X 1 , X 2 and Y are chosen such that there are between 6 and 15 atoms in the normal chain. In one specific embodiment of the compounds of the invention X 1 , X 2 and Y are chosen such that there are 7 atoms in the normal chain. In another specific embodiment of the compounds of the invention X 1 , X 2 and Y are chosen such that there are 8 atoms in the normal chain.
  • X 1 and X 2 are each independently a heteroalkyl group containing at least one oxygen atom in the normal chain.
  • X 1 is selected from the group consisting of:
  • X 1 is selected from the group consisting of:
  • X 1 is -OCH 2 -. In another specific embodiment X 1 is
  • X 1 is -CH 2 O-. In another specific embodiment X 1 is -OCH 2 CH 2 -. In another specific embodiment X 1 is -CH 2 CH 2 O-. In another specific embodiment X 1 is -CH 2 OCH 2 -. In another specific embodiment X 1 is -CH 2 CH 2 OCH 2 -.
  • X 2 is selected from the group consisting of:
  • X 2 is selected from the group consisting of:
  • X 2 is -OCH 2 -. In another specific embodiment X 1 is -CH 2 O-. In another specific embodiment X 2 is -OCH 2 CH 2 -. In another specific embodiment X 2 is -CH 2 CH 2 O-. In another specific embodiment X 2 is -CH 2 OCH 2 -. In another specific embodiment X 2 is -CH 2 CH 2 OCH 2 -.
  • X 1 is -OCH 2 CH 2 - and X 2 is -CH 2 OCH 2 - This provides compounds of formula (Ia).
  • R 1 , R 2 , R 3 , Y, m, and n are as defined above, or a pharmaceutically acceptable salt, N-oxide, or prodrug thereof.
  • Y is selected from the group consisting of:
  • Y is a cyclopropyl group.
  • X 1 is -OCH 2 CH 2 - and X 2 is -CH 2 OCH 2 - and Y is
  • R 1 , R 2 , R 3 , m, and n are as defined above, or a pharmaceutically acceptable salt, N-oxide, or prodrug thereof.
  • R 1 is selected from the group consisting of H, Cl, F, methyl, and methoxy. In one specific embodiment R 1 is H. In another specific embodiment R 1 is Cl. In one specific embodiment R 1 is F. In another specific embodiment R 1 is methyl. In another specific embodiment R 1 is methoxy.
  • R 2 is selected from the group consisting of H, chloro, bromo, iodo, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, phenyl, hydroxy, methoxy, ethoxy, phenoxy, benzyloxy, amino, methylamino, ethylamino, propylamino, butylamino, pentylamino and hexylamino, each of which may be optionally substituted.
  • R 2 is selected from the group consisting of H, chloro, bromo, iodo, amino, methylamino, ethylamino, propylamino, butylamino, pentylamino and hexylamino, each of which may be optionally substituted.
  • R 2 is H.
  • n is 0. In certain embodiments n is 1.
  • each R 3 is independently selected from the group consisting of halogen, OH 1 NO 2 , cyano, NH 2 , optionally substituted Ci-C 12 alkyl, optionally substituted C r C 10 heteroalkyl, optionally substituted CrC ⁇ alkyloxy, SR 3 , SO 3 H, SO 3 NH 2 ,
  • each R 3 is independently selected from the group consisting of optionally substituted Ci-Ci 0 heteroalkyl, optionally substituted CrCi 2 heterocycloalkyl, and optionally substituted C r C 12 alkyloxy.
  • each R 3 is an optionally substituted d-C 12 alkyloxy of the formula:
  • A is selected from the group consisting of a bond, O and CH 2 ;
  • B is selected from the group consisting of O and CH 2;
  • D is selected from the group consisting of N and CR 12 ;
  • p is an integer selected from the group consisting of 0, 1 , 2, 3, 4, 5, and 6;
  • R 10 and R 11 are independently selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 1 -C 10 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted C 1 -C 12 heterocycloalkyl, optionally substituted C 1 -C 12 heterocycloalkenyl, optionally substituted C 6 -C 18 aryl, and optionally substituted CrC ⁇ heteroaryl, or
  • R 10 and R 11 when taken together with the atom to which they are attached form an optionally substituted cyclic moiety
  • R 12 is H or optionally substituted C 1 -C 6 alkyl.
  • A is CH 2 . In one specific embodiment A is O.
  • B is O. In one specific embodiment B is CH 2 .
  • A is O and B is CH 2 .
  • p is an integer selected from the group consisting of 0, 1, 2, 3,
  • p is 0. In one specific embodiment p is 1. In one specific embodiment p is 2. In one specific embodiment p is 3. In one specific embodiment p is 4. In one specific embodiment p is 5. In one specific embodiment p is 6.
  • D is N.
  • D is CH.
  • R 10 and R 11 when taken together form an optionally substituted cyclic moiety.
  • the optionally substituted cyclic moiety may be any suitable cyclic moiety including a C 1 -C 10 cycloalkyl or a Ci-C 10 heterocycloalkyl moiety.
  • D is N and R 10 and R 11 when taken together with the nitrogen atom to which they are attached form an optionally substituted piperidinyl moiety.
  • R 10 and R 11 when taken together with the nitrogen atom to which they are attached form 4-methyl-piperidin-1-yl.
  • R 10 and R 11 when taken together with the nitrogen atom to which they are attached form a pyrrolidinyl moiety.
  • R 3 is:
  • each R 3 is independently selected from the group consisting of:
  • R 4 is selected from the group consisting of H and C 1 -C 4 alkyl. In a specific embodiment R 4 is C 1 -C 4 alkyl. In another specific embodiment R 4 is H.
  • R 5 is selected from the group consisting of C 1 -C 4 alkyl, heteroalkyl and acyl. In a specific embodiment R 5 is C 1 -C 4 alkyl. In another specific embodiment R 5 is H.
  • R 6 is H, optionally substituted d-C ⁇ alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted Ci-C 10 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -d 2 cycloalkenyl, optionally substituted C 1 -C 12 heterocycloalkyl, optionally substituted C 1 -C 12 heterocycloalkenyl, optionally substituted C 6 -C 18 aryl, optionally substituted Crdeheteroaryl, and acyl.
  • the embodiments disclosed are also directed to pharmaceutically acceptable salts, pharmaceutically acceptable N-oxides, pharmaceutically acceptable prodrugs, and pharmaceutically active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites.
  • the invention also relates to pharmaceutical compositions including a compound of the invention with a pharmaceutically acceptable carrier, diluent or excipient.
  • the invention provides a method of inhibiting one or more protein kinase(s) including exposing the one or more protein kinase(s) and/or co-factor(s) thereof to an effective amount of a compound of the invention.
  • the compounds disclosed herein may act directly and solely on the kinase molecule to inhibit biological activity. However, it is understood that the compounds may also act at least partially on co-factors that are involved in the phosphorylation process. For example, where the kinase is cyclin-dependent, a co-factor such as cyclinA is involved in the transfer of phosphate from ATP (also considered a co-factor in itself) to the substrate molecule.
  • co-factors include ionic species (such as zinc and calcium), lipids (such as phosphatidylserine), and diacylglycerols.
  • the one or more protein kinase(s) is a cyclin-dependent protein kinase.
  • the cyclin-dependent kinase is a Group I CMCG kinase.
  • the Group I CMCG kinase is selected from the group consisting of CDC2Hs, CDK2, CDK3, CDK4, CDK5, CDK6, CDK9, PCTAIRE1, PCTAIRE2, PCTAIRE3, CAK/MO15, Dm2, Dm2c, Ddcdc2, DdPRK, LmmCRKI , PfC2R, EhC2R, CfCdc2R, cdc2+, CDC28, PHO85, KIN28, FpCdc2, MsCdc2B, and OsC2R or a functional equivalent thereof.
  • the Group I CMCG kinase is CDK2 or a functional equivalent thereof.
  • the one or more protein kinase(s) is a protein tyrosine kinase.
  • the protein tyrosine kinase is a Group VII protein tyrosine kinase.
  • the Group VII protein tyrosine kinase is selected from the group consisting of TYK2, JAK1 , JAK2 and HOP or a functional equivalent thereof.
  • the Group VII protein tyrosine kinase is JAK2 or a functional equivalent thereof.
  • the JAK2 includes a recurrent unique acquired clonal mutation.
  • This mutation is observed in a majority of polycythemia vera (PV) patients and a significant proportion of patients with other myeloproliferative disorders, including, essential thrombocythemia (ET) and chronic idiopathic myelofibrosis (IMF).
  • the mutation is a valine to phenylalanine substitution at position 617 (V617F).
  • V617F valine to phenylalanine substitution at position 617
  • the JAK2 mutation is somatic and occurs at the level of a hematopoietic stem cell.
  • myeloid cells i.e., bone marrow cells, granulocytes, platelets and erythroblasts derived from CD34+ cells, but not in T cells.
  • mutant JAK2 was found in hematopoietic colonies derived from hematopoietic progenitor cells. Applicant has demonstrated that kinase inhibitors described herein are capable of inhibiting the activity of wild type and mutant JAK2.
  • the protein tyrosine kinase is a Group XIV protein tyrosine kinase.
  • the Group XIV protein tyrosine kinase is selected from the group consisting of PDGFR-b, PDGFR-a, CSF1R, c-kit, Flk2, FLT1, FLT2, FLT3 and FLT4 or a functional equivalent thereof.
  • the Group XIV protein tyrosine kinase is FLT3 or a functional equivalent thereof.
  • the FLT3 kinase includes a mutation.
  • FLT3 mutations are important in the initiation or maintenance of AML in some patients.
  • Activating mutations of FLT3 result in constitutive activation of FLT3 tyrosine kinase activity and can transform factor-dependent hematopoietic cells as evidenced by conversion to factor-independent growth and formation of tumours in immunodeficient mice.
  • retroviral transduction of primary murine bone marrow with an AML patient-derived FLT3 ITD (internal tandem duplication) cDNA results in a lethal myeloproliferative syndrome.
  • kinase inhibitors described herein are capable of inhibiting FLT3 including an ITD where there is a duplication of amino acids VDFREYEYDH at amino acid position 592-601.
  • the FLT3 includes an internal tandem duplication.
  • the internal tandem duplication is a duplication of amino acids VDFREYEYDH at position 592-601.
  • exposing the one or more protein kinase(s) to the compound includes administering the compound to a mammal containing the one or more protein kinase(s).
  • the one or more protein kinase(s) include at least two kinases selected from the group consisting of CDK2, FLT3 and JAK2 or functional equivalents thereof. In one form of this embodiment the one or more protein kinase(s) include all three of CDK2, FLT3 and JAK2 or functional equivalents thereof.
  • the invention provides the use of a compound of the invention to inhibit one or more protein kinase(s).
  • the one or more protein kinase(s) is a cyclin-dependent protein kinase.
  • the cyclin-dependent kinase is a Group I CMCG kinase.
  • the Group I CMCG kinase is selected from the group consisting of CDC2Hs, CDK2, CDK3, CDK4, CDK5, CDK6, CDK9, PCTAIRE1, PCTAIRE2, PCTAIRE3, CAK/MO15, Dm2, Dm2c, Ddcdc2, DdPRK, LmmCRKI , PfC2R, EhC2R, CfCdc2R, cdc2+, CDC28, PHO85, KIN28, FpCdc2, MsCdc2B, and OsC2R and functional equivalents thereof.
  • the Group I CMCG kinase is CDK2 or a functional equivalent thereof.
  • the one or more protein kinase(s) is a protein tyrosine kinase.
  • the protein tyrosine kinase is a Group VII protein tyrosine kinase.
  • the Group VII protein tyrosine kinase is selected from the group consisting of TYK2, JAK1, JAK2 and HOP or a functional equivalent thereof.
  • the Group VII protein tyrosine kinase is JAK2 or a functional equivalent thereof.
  • the JAK2 includes a V to F mutation at position 617.
  • the protein tyrosine kinase is a Group XIV protein tyrosine kinase.
  • the Group XIV protein tyrosine kinase is selected from the group consisting of PDGFR-b, PDGFR-a, CSF1R, c-kit, Flk2, FLT1, FLT2, FLT3 and FLT4 or a functional equivalent thereof.
  • the Group XIV protein tyrosine kinase is FLT3 or a functional equivalent thereof.
  • FLT3 includes an internal tandem duplication.
  • the internal tandem duplication is a duplication of amino acids VDFREYEYDH at position 592-601.
  • the one or more protein kinase(s) include at least two kinases selected from the group consisting of CDK2, FLT3 and JAK2 or functional equivalents thereof. In one form of this embodiment the one or more protein kinase(s) include all three of CDK2, FLT3 and JAK2 or functional equivalents thereof.
  • the invention provides a method of treating or preventing a condition in a mammal in which inhibition of one or more protein kinase(s) and/or co-factor(s) thereof prevents, inhibits or ameliorates a pathology or a symptomology of the condition, the method including administration of a therapeutically effective amount of a compound of the invention.
  • the one or more protein kinase(s) is a cyclin-dependent protein kinase.
  • the cyclin-dependent kinase is a
  • Group I CMCG kinase is selected from the group consisting of CDC2Hs, CDK2, CDK3, CDK4, CDK5, CDK6, CDK9, PCTAIRE1 ,
  • the Group I CMCG kinase is CDK2 or a functional equivalent thereof.
  • the condition is selected from the group consisting of prostate cancer, retinoblastoma, malignant neoplasm of breast, malignant tumour of colon, endometrial hyperplasia, osteosarcoma, squamous cell carcinoma, non-small cell lung cancer, melanoma, liver cell carcinoma, malignant neoplasm of pancreas, myeloid leukaemia, cervical carcinoma, fibroid tumour, adenocarcinoma of the colon, T-cell leukaemia, glioma, glioblastoma, oligodendroglioma, lymphoma, ovarian cancer, restenosis, astrocytoma, bladder neoplasms, musculoskeletal neoplasms and Alzheimer's Disease.
  • the one or more protein kinase(s) is a protein tyrosine kinase.
  • the protein tyrosine kinase is a Group VII protein tyrosine kinase.
  • the Group VII protein tyrosine kinase is selected from the group consisting of TYK2, JAK1 , JAK2 and HOP or a functional equivalent thereof.
  • the Group VII protein tyrosine kinase is JAK2 or a functional equivalent thereof.
  • the JAK2 includes a V to F mutation at position 617.
  • the condition is selected from the group consisting of Myeloproliferative disorders (chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukemia), myeloid metaplasia, chronic myelomonocytic leukemia, acute lymphocytic leukemia, acute erythroblastic leukemia, Hodgkin's disease, B-cell lymphoma, acute T-cell leukemia, breast carcinoma, ovarian cancer, colon carcinoma, prostate cancer, melanoma, myelodysplastic syndromes, keloids, congestive heart failure, ischemia, thrombosis, cardiac hypertrophy, pulmonary hypertension, and retinal degeneration.
  • Myeloproliferative disorders chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukemia), myeloid metaplasia, chronic myelo
  • the condition is an inflammatory disorder and/or an autoimmune disorder.
  • disorders of this type that may be treated include acute disseminated encephalomyelitis, Addison's disease, agammaglobulinemia, agranulocytosis, allergic asthma, allergic encephalomyelitis, allergic rhinitis, alopecia areata, alopecia senilis, anerythroplasia, ankylosing spondylitis, antiphospholipid antibody syndrome, aortitis syndrome, aplastic anemia, atopic dermatitis, autoimmune haemolytic anemia, autoimmune hepatitis, autoimmune oophoritis, BaIo disease, Basedow's disease, Behcet's disease, bronchial asthma, Castleman's syndrome, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, Cogans syndrome, comical cornea, comical leukoma, Co
  • the disorder is selected from the group consisting of ankylosing spondylitis, Graves' disease, inflammatory bowel diseases (Crohn's disease, ulcerative colitis), multiple sclerosis, psoriasis and rheumatoid arthritis.
  • the protein tyrosine kinase is a Group XIV protein tyrosine kinase.
  • the Group XIV protein tyrosine kinase is selected from the group consisting of PDGFR-b, PDGFR-a, CSF1R, c-kit, Flk2, FLT1, FLT2, FLT3 and FLT4 or a functional equivalent thereof.
  • the Group XIV protein tyrosine kinase is FLT3 or a functional equivalent thereof.
  • FLT3 includes an internal tandem duplication.
  • the internal tandem duplication is a duplication of amino acids VDFREYEYDH at position 592-601.
  • the condition is selected from the group consisting of acute myeloid leukemia, acute promyelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, leukocytosis, juvenile myelomonocytic leukemia, acute B-cell leukemia, chronic myeloid leukemia, acute T-cell leukemia, myeloproliferative disorders, and chronic myelomonocytic leukemia.
  • the one or more protein kinase(s) include at least two kinases selected from the group consisting of CDK2, FLT3 and JAK2 or functional equivalents thereof. In one form of this embodiment the one or more protein kinase(s) include all three of CDK2, FLT3 and JAK2 or functional equivalents thereof.
  • the invention provides the use of a compound of the invention in the preparation of a medicament for treating a condition in an animal in which inhibition of one or more protein kinase(s) can prevent, inhibit or ameliorate the pathology or symptomology of the condition.
  • the one or more protein kinase(s) is a cyclin-dependent protein kinase.
  • the cyclin-dependent kinase is a Group I CMCG kinase.
  • the Group I CMCG kinase is selected from the group consisting of CDC2Hs, CDK2, CDK3, CDK4, CDK5, CDK6, CDK9, PCTAIRE1 ,
  • PCTAIRE2 PCTAIRE3, CAK/MO15, Dm2, Dm2c, Ddcdc2, DdPRK, LmmCRKI, PfC2R,
  • the Group I CMCG kinase is
  • the condition is selected from the group consisting of prostate cancer, retinoblastoma, malignant neoplasm of breast, malignant tumour of colon, endometrial hyperplasia, osteosarcoma, squamous cell carcinoma, non-small cell lung cancer, melanoma, liver cell carcinoma, malignant neoplasm of pancreas, myeloid leukemia, cervical carcinoma, fibroid tumour, adenocarcinoma of the colon, T-cell leukemia, glioma, glioblastoma, oligodendroglioma, lymphoma, ovarian cancer, restenosis, astrocytoma, bladder neoplasms, musculoskeletal neoplasms and Alzheimer's Disease.
  • the one or more protein kinase(s) is a protein tyrosine kinase.
  • the protein tyrosine kinase is a Group VII protein tyrosine kinase.
  • the Group VII protein tyrosine kinase is selected from the group consisting of TYK2, JAK1, JAK2 and HOP or a functional equivalent thereof.
  • the Group VII protein tyrosine kinase is JAK2 or a functional equivalent thereof.
  • the JAK2 includes a V to F mutation at position 617.
  • the condition is selected from the group consisting of Myeloproliferative disorders (chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukemia), myeloid metaplasia, chronic myelomonocytic leukemia, acute lymphocytic leukemia, acute erythroblastic leukemia, Hodgkin's disease, B-cell lymphoma, acute T-cell leukemia, breast carcinoma, ovarian cancer, colon carcinoma, prostate cancer, melanoma, myelodysplastic syndromes, keloids, congestive heart failure, ischemia, thrombosis, cardiac hypertrophy, pulmonary hypertension, and retinal degeneration.
  • Myeloproliferative disorders chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukemia), myeloid metaplasia, chronic myelo
  • the condition is an inflammatory disorder and/or an autoimmune disorder.
  • disorders of this type that may be treated include acute disseminated encephalomyelitis, Addison's disease, agammaglobulinemia, agranulocytosis, allergic asthma, allergic encephalomyelitis, allergic rhinitis, alopecia areata, alopecia senilis, anerythroplasia, ankylosing spondylitis, antiphospholipid antibody syndrome, aortitis syndrome, aplastic anemia, atopic dermatitis, autoimmune haemolytic anemia, autoimmune hepatitis, autoimmune oophoritis, BaIo disease, Basedow's disease, Behcet's disease, bronchial asthma, Castleman's syndrome, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, Cogans syndrome, comical cornea, comical leukoma
  • the disorder is selected from the group consisting of ankylosing spondylitis, Graves' disease, inflammatory bowel diseases (Crohn's disease, ulcerative colitis), multiple sclerosis, psoriasis and rheumatoid arthritis.
  • the protein tyrosine kinase is a Group XIV protein tyrosine kinase.
  • the Group XIV protein tyrosine kinase is selected from the group consisting of PDGFR-b, PDGFR-a, CSF1R, c-kit, Flk2, FLT1, FLT2, FLT3 and FLT4 or a functional equivalent thereof.
  • the Group XIV protein tyrosine kinase is FLT3 or a functional equivalent thereof.
  • FLT3 includes an internal tandem duplication.
  • the internal tandem duplication is a duplication of amino acids VDFREYEYDH at position 592-601.
  • the condition is selected from the group consisting of acute myeloid leukemia, acute promyelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, leukocytosis, juvenile myelomonocytic leukemia, acute B-cell leukemia, chronic myeloid leukemia, acute T-cell leukemia, myeloproliferative disorders, and chronic myelomonocytic leukemia.
  • the one or more protein kinase(s) include at least two kinases selected from the group consisting of CDK2, FLT3 and JAK2 or functional equivalents thereof.
  • the one or more protein kihase(s) include all three of CDK2, FLT3 and JAK2 or functional equivalents thereof.
  • the invention provides the use of a compound of the invention in the preparation of a medicament for the treatment or prevention of a kinase-related disorder.
  • the kinase-related disorder is a proliferative disorder.
  • the proliferative disorder is elected from the group consisting of myeloproliferative disorders (chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukaemia), myeloid metaplasia, chronic myelomonocytic leukaemia, acute myeloid leukaemia, juvenile myelomonocytic leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia, acute erythroblastic leukaemia, acute B-cell leukaemia, leukocytosis, Hodgkin's disease, B-cell lymphoma, acute T-cell leukaemia, breast carcinoma, ovarian cancer, colon carcinoma, prostate cancer, melanoma, myelodysplastic syndromes, keloids, retinoblastoma, mal
  • the proliferative disorder is a myeloproliferative disorder.
  • the myeloproliferative disorder is selected from the group consisting of polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis.
  • the proliferative disorder is cancer.
  • the cancer is a solid tumour.
  • the solid tumour is a tumour present in or metastasized from an organ or tissue selected from the group consisting of breast, ovary, colon, prostate, endometrium, bone, skin, lung, liver, pancreas, cervix, brain, neural tissue, lymphatic tissue, blood vessel, bladder and muscle.
  • the cancer is a haematological cancer.
  • the haematological cancer is selected from the group consisting of acute myeloid leukaemia, acute promyelocyte leukaemia, acute lymphocytic leukaemia, myelodysplastic syndrome, leukocytosis, juvenile myelomonocytic leukaemia, acute B-cell leukaemia, chronic myeloid leukaemia, acute T-cell leukaemia, chronic myelomonocytic leukaemia, myeloid metaplasia, chronic myelomonocytic leukaemia, acute erythroblastic leukaemia, Hodgkin's disease, and B-cell lymphoma.
  • the condition is an inflammatory disorder and/or an autoimmune disorder.
  • disorders of this type that may be treated include acute disseminated encephalomyelitis, Addison's disease, agammaglobulinemia, agranulocytosis, allergic asthma, allergic encephalomyelitis, allergic rhinitis, alopecia areata, alopecia senilis, aner ⁇ throplasia, ankylosing spondylitis, antiphospholipid antibody syndrome, aortitis syndrome, aplastic anemia, atopic dermatitis, autoimmune haemolytic anemia, autoimmune hepatitis, autoimmune oophoritis, BaIo disease, Basedow's disease, Behcet's disease, bronchial asthma, Castleman's syndrome, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, Cogans syndrome, comical cornea, comical leukoma,
  • the disorder is selected from the group consisting of ankylosing spondylitis, Graves' disease, inflammatory bowel diseases (Crohn's disease, ulcerative colitis), multiple sclerosis, psoriasis and rheumatoid arthritis.
  • the kinase-related disorder is a cardiovascular disorder.
  • the cardiovascular disorder is selected from the group consisting of congestive heart failure, ischemia, thrombosis, cardiac hypertrophy and restenosis.
  • the kinase-related disorder is a neurodegenerative disorder.
  • the neurodegenerative disorder is Alzheimer's disease.
  • the invention provides a method of treating or preventing a kinase-related disorder including administration of a therapeutically effective amount of a compound of the invention to a patient in need thereof.
  • the kinase-related disorder is a proliferative disorder.
  • the proliferative disorder is elected from the group consisting of myeloproliferative disorders (chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukaemia), myeloid metaplasia, chronic myelomonocytic leukaemia, acute myeloid leukaemia, juvenile myelomonocytic leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia, acute erythroblastic leukaemia, acute B-cell leukaemia, leukocytosis, Hodgkin's disease, B-cell lymphoma, acute T-cell leukaemia, breast carcinoma, ovarian cancer, colon carcinoma, prostate cancer, melanoma, myelodysplastic syndromes, keloids, retinoblastoma, malignant neoplasm of breast, malignant tumour of colon, endometrial hyperp
  • the proliferative disorder is a myeloproliferative disorder.
  • the myeloproliferative disorder is selected from the group consisting of polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis.
  • the proliferative disorder is cancer.
  • the cancer is a solid tumour.
  • the solid tumour is a tumour present in or metastasized from an organ or tissue selected from the group consisting of breast, ovary, colon, prostate, endometrium, bone, skin, lung, liver, pancreas, cervix, brain, neural tissue, lymphatic tissue, blood vessel, bladder and muscle.
  • the cancer is a haematological cancer.
  • the haematological cancer is selected from the group consisting of acute myeloid leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia, myelodysplastic syndrome, leukocytosis, juvenile myelomonocytic leukaemia, acute B-cell leukaemia, chronic myeloid leukaemia, acute T-cell leukaemia, chronic myelomonocytic leukaemia, myeloid metaplasia, chronic myelomonocytic leukaemia, acute erythroblastic leukaemia, Hodgkin's disease, and B-cell lymphoma.
  • the condition is an inflammatory disorder and/or an autoimmune disorder.
  • disorders of this type that may be treated include acute disseminated encephalomyelitis, Addison's disease, agammaglobulinemia, agranulocytosis, allergic asthma, allergic encephalomyelitis, allergic rhinitis, alopecia areata, alopecia senilis, anerythroplasia, ankylosing spondylitis, antiphospholipid antibody syndrome, aortitis syndrome, aplastic anemia, atopic dermatitis, autoimmune haemolytic anemia, autoimmune hepatitis, autoimmune oophoritis, BaIo disease, Basedow's disease, Behcet's disease, bronchial asthma, Castleman's syndrome, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, Cogans syndrome, comical cornea, comical leukoma, Co
  • the disorder is selected from the group consisting of ankylosing spondylitis, Graves' disease, inflammatory bowel diseases (Crohn's disease, ulcerative colitis), multiple sclerosis, psoriasis and rheumatoid arthritis.
  • the kinase-related disorder is a cardiovascular disorder.
  • the cardiovascular disorder is selected from the group consisting of congestive heart failure, ischemia, thrombosis, cardiac hypertrophy and restenosis.
  • the kinase-related disorder is a neurodegenerative disorder.
  • the neurodegenerative disorder is Alzheimer's disease.
  • the invention also provides a method for inhibiting cell proliferation including administration of an effective amount of a compound according to formula (I).
  • the term "optionally substituted” as used throughout the specification denotes that the group may or may not be further substituted or fused (so as to form a condensed polycyclic system), with one or more non-hydrogen substituent groups.
  • Alkyl as a group or part of a group refers to a straight or branched aliphatic hydrocarbon group, preferably a C 1 -C 14 alkyl, more preferably C 1 -C 10 alkyl, most preferably C 1 -C 6 unless otherwise noted. Examples of suitable straight and branched
  • C 1 -C 6 alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, hexyl, and the like.
  • the group may be a terminal group or a bridging group.
  • Alkylamino includes both mono-alkylamino and dialkylamino, unless specified.
  • “Mono-alkylamino” means a -NH-Alkyl group, in which alkyl is as defined above.
  • Dialkylamino means a -N(alkyl) 2 group, in which each alkyl may be the same or different and are each as defined herein for alkyl.
  • the alkyl group is preferably a C 1 -C 6 alkyl group.
  • the group may be a terminal group or a bridging group.
  • Arylamino includes both mono-arylamino and di-arylamino unless specified.
  • Mono-arylamino means a group of formula arylNH-, in which aryl is as defined herein.
  • di-arylamino means a group of formula (aryl) 2 N- where each aryl may be the same or different and are each as defined herein for aryl.
  • the group may be a terminal group or a bridging group.
  • acyl means an alkyl-CO- group in which the alkyl group is as described herein.
  • examples of acyl include acetyl and benzoyl.
  • the alkyl group is preferably a C 1 -C 6 alkyl group.
  • the group may be a terminal group or a bridging group.
  • Alkenyl as a group or part of a group denotes an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched preferably having 2-14 carbon atoms, more preferably 2-12 carbon atoms, most preferably 2-6 carbon atoms, in the normal chain.
  • the group may contain a plurality of double bonds in the normal chain and the orientation about each is independently E or Z.
  • Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl and nonenyl.
  • the group may be a terminal group or a bridging group.
  • Alkoxy refers to an -O-alkyl group in which alkyl is defined herein. Preferably the alkoxy is a C!-C 6 alkoxy. Examples include, but are not limited to, methoxy and ethoxy.
  • the group may be a terminal group or a bridging group.
  • Alkenyloxy refers to an -O- alkenyl group in which alkenyl is as defined herein. Preferred alkenyloxy groups are C 1 -C 6 alkenyloxy groups.
  • the group may be a terminal group or a bridging group.
  • Alkynyloxy refers to an -O-alkynyl group in which alkynyl is as defined herein.
  • Preferred alkynyloxy groups are C 1 -C 6 alkynyloxy groups.
  • the group may be a terminal group or a bridging group.
  • Alkoxycarbonyl refers to an -C(O)-O-alkyl group in which alkyl is as defined herein.
  • the alkyl group is preferably a C 1 -C 6 alkyl group. Examples include, but not limited to, methoxycarbonyl and ethoxycarbonyl.
  • the group may be a terminal group or a bridging group.
  • Alkylsulfinyl means a -S(O)-alkyl group in which alkyl is as defined above.
  • the alkyl group is preferably a C 1 -C 6 alkyl group.
  • Exemplary alkylsulfinyl groups include, but not limited to, methylsulfinyl and ethylsulfinyl.
  • the group may be a terminal group or a bridging group.
  • Alkylsulfonyl refers to a -S(O) 2 -alkyl group in which alkyl is as defined above.
  • the alkyl group is preferably a C 1 -C 6 alkyl group. Examples include, but not limited to methylsulfonyl and ethylsulfonyl.
  • the group may be a terminal group or a bridging group.
  • Alkynyl as a group or part of a group means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched preferably having from 2-14 carbon atoms, more preferably 2-12 carbon atoms, more preferably 2-6 carbon atoms in the normal chain.
  • Exemplary structures include, but are not limited to, ethynyl and propynyl.
  • the group may be a terminal group or a bridging group.
  • Alkylaminocarbonyl refers to an alkylamino-carbonyl group in which alkylamino is as defined above.
  • the group may be a terminal group or a bridging group.
  • Cycloalkyl refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle preferably containing from 3 to 9 carbons per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwise specified. It includes monocyclic systems such as cyclopropyl and cyclohexyl, bicyclic systems such as decalin, and polycyclic systems such as adamantane. The group may be a terminal group or a bridging group.
  • Cycloalkenyl means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and preferably having from 5-10 carbon atoms per ring.
  • Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl.
  • the cycloalkenyl group may be substituted by one or more substituent groups.
  • the group may be a terminal group or a bridging group.
  • alkyl and cycloalkyl substituents also applies to the alkyl portions of other substituents, such as without limitation, alkoxy, alkyl amines, alkyl ketones, arylalkyl, heteroarylalkyl, alkylsulfonyl and alkyl ester substituents and the like.
  • Cycloalkylalkyl means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described.
  • Exemplary monocycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
  • the group may be a terminal group or a bridging group.
  • Halogen represents chlorine, fluorine, bromine or iodine.
  • Heterocycloalkyl refers to a saturated or partially saturated monocyclic, bicyclic, or polycyclic ring containing at least one heteroatom selected from nitrogen, sulfur, oxygen, preferably from 1 to.3 heteroatoms in at least one ring. Each ring is preferably from 3 to 10 membered, more preferably 4 to 7 membered.
  • heterocycloalkyl substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1 ,3-diazapane, 1 ,4-diazapane, 1,4- oxazepane, and 1 ,4-oxathiapane.
  • the group may be a terminal group or a bridging group.
  • Heterocycloalkenyl refers to a heterocycloalkyl as described above but containing at least one double bond.
  • the group may be a terminal group or a bridging group.
  • Heterocycloalkylalkyl refers to a heterocycloalkyl-alkyl group in which the heterocycloalkyl and alkyl moieties are as previously described.
  • exemplary heterocycloalkylalkyl groups include (2-tetrahydrofuryl)methyl, (2-tetrahydrothiofuranyl) methyl.
  • the group may be a terminal group or a bridging group.
  • Heteroalkyl refers to a straight- or branched-chain alkyl group preferably having from 2 to 14 carbons, more preferably 2 to 10 carbons in the chain, one or more of which has been replaced by a heteroatom selected from S, O, P and N.
  • heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, amides, alkyl sulfides, and the like.
  • the group may be a terminal group or a bridging group.
  • reference to the normal chain when used in the context of a bridging group refers to the direct chain of atoms linking the two terminal positions of the bridging group.
  • Aryl as a group or part of a group denotes (i) an optionally substituted monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) preferably having from 5 to 12 atoms per ring.
  • aryl groups include phenyl, naphthyl, and the like; (ii) an optionally substituted partially saturated bicyclic aromatic carbocyclic moiety in which a phenyl and a C 5-7 cycloalkyi or C 5-7 cycloalkenyl group are fused together to form a cyclic structure, such as tetrahydronaphthyl, indenyl or indanyl.
  • the group may be a terminal group or a bridging group.
  • Arylalkenyl means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described.
  • exemplary arylalkenyl groups include phenylallyl.
  • the group may be a terminal group or a bridging group.
  • Arylalkyl means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C 1-5 alkyl moiety. Exemplary arylalkyl groups include benzyl, phenethyl and naphthelenemethyl. The group may be a terminal group or a bridging group.
  • Heteroaryl either alone or part of a group refers to groups containing an aromatic ring (preferably a 5 or 6 membered aromatic ring) having one or more heteroatoms as ring atoms in the aromatic ring with the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include nitrogen, oxygen and sulphur.
  • heteroaryl examples include thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, fura ⁇ , isoindolizine, xantholene, phenoxatine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indole, isoindole, 1H-indazole, purine, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, cinnoline, carbazole, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isooxazole, furazane, phenoxazine, 2-
  • the group may be a terminal group or a bridging group.
  • Heteroarylalkyl means a heteroaryl-alkyl group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a lower alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
  • the group may be a terminal group or a bridging group.
  • “Lower alkyl” as a group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain, more preferably 1 to 4 carbons such as methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, isobutyl or tertiary-butyl).
  • the group may be a terminal group or a bridging group.
  • Some of the compounds of the disclosed embodiments may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and /or diastereomers. All such single stereoisomers, racemates and mixtures thereof, are intended to be within the scope of the subject matter described and claimed.
  • Formula (I) is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds.
  • each formula includes compounds having the indicated structure, including the hydrated as well as the non-hydrated forms.
  • the compounds of the various embodiments include pharmaceutically acceptable salts, prodrugs, N-oxides and active metabolites of such compounds, and pharmaceutically acceptable salts of such metabolites.
  • pharmaceutically acceptable salts refers to salts that retain the desired biological activity of the above-identified compounds, and include pharmaceutically acceptable acid addition salts and base addition salts.
  • Suitable pharmaceutically acceptable acid addition salts of compounds of Formula (I) may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric, and phosphoric acid.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic, arylsulfonic.
  • Suitable pharmaceutically acceptable base addition salts of compounds of Formula (I) include metallic salts made from lithium, sodium, potassium, magnesium, calcium, aluminium, and zinc, and organic salts made from organic bases such as choline, diethanolamine, morpholine.
  • organic salts are: ammonium salts, quaternary salts such as tetramethylammonium salt; amino acid addition salts such as salts with glycine and arginine. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, PA 1995. In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.
  • Prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of formula (I).
  • metabolic means e.g. by hydrolysis, reduction or oxidation
  • an ester prodrug of a compound of formula (I) containing a hydroxyl group may be convertible by hydrolysis in vivo to the parent molecule.
  • Suitable esters of compounds of formula (I) containing a hydroxyl group are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.
  • ester prodrug of a compound of formula (I) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.
  • ester prodrugs are those described by F.J. Leinweber, Drug Metab. Res., 18:379, 1987).
  • terapéuticaally effective amount or “effective amount” is an amount sufficient to effect beneficial or desired clinical results.
  • An effective amount can be administered in one or more administrations.
  • An effective amount is typically sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state.
  • normal chain refers to the direct chain joining the two ends of a linking moiety.
  • an alkoxyalkyl group is a heteroalkyl group containing a heteroatom in the normal chain (in this case an oxygen atom).
  • An amide group is also a heteroalkyl group but it does not contain an oxygen atom in the normal chain (it has a nitrogen atom in the normal chain).
  • kinases may have isoforms, such that while the primary, secondary, tertiary or quaternary structure of a given kinase isoform is different to the protoypical kinase, the molecule maintains biological activity as a protein kinase. Isoforms may arise from normal allelic variation within a population and include mutations such as amino acid substitution, deletion, addition, truncation, or duplication. Also included within the term “functional equivalent” are variants generated at the level of transcription. Many kinases (including JAK2 and CDK2) have isoforms that arise from transcript variation. It is also known that FLT3 has an isoform that is the result of exon-skipping. Other functional equivalents include kinases having altered post-translational modification such as glycosylation.
  • the compounds of the invention have the ability to inhibit the activity of certain protein kinases.
  • the ability to inhibit kinase activity may be a result of the compounds of the invention acting directly and solely on the kinase molecule to inhibit biological activity.
  • the compounds may also act at least partially on co-factors of the kinase in question that are involved in the phosphorylation process.
  • co-factors include ionic species (such as zinc and calcium), lipids (such as phosphatidylserine), and diacylglycerols.
  • the compounds may have activity against a wide range of protein kinases.
  • One suitable family of protein kinases are the cyclin-dependent protein kinases.
  • An example of the cyclin-dependent kinases is the Group I CMCG kinases.
  • Group I CMCG kinases include CDC2Hs, CDK2, CDK3, CDK4, CDK5, CDK6, CDK9, PCTAIRE1, PCTAIRE2, PCTAIRE3, CAK/MO15, Dm2, Dm2c, Ddcdc2, DdPRK, LmmCRKI, PfC2R, EhC2R, CfCdc2R, cdc2+, CDC28, PHO85, KIN28, FpCdc2, MsCdc2B, and OsC2R.
  • a Group I CMCG kinase of particular interest is CDK2.
  • protein tyrosine kinases Another family of protein kinases are protein tyrosine kinases.
  • An example of protein tyrosine kinases is a Group VII protein tyrosine kinase.
  • Examples of Group VII protein tyrosine kinase include TYK2, JAK1, JAK2 and HOP.
  • a protein kinase of particular interest is the Group VII protein tyrosine kinase JAK2.
  • the JAK2 protein kinase may include a recurrent unique acquired clonal mutation.
  • PV polycythemia vera
  • IMF chronic idiopathic myelofibrosis
  • protein tyrosine kinases is the Group XIV protein tyrosine kinases.
  • Examples of the Group XIV protein tyrosine kinase include PDGFR-b, PDGFR- a, CSF1R, c-kit, Flk2, FLT1, FLT2, FLT3 and FLT4.
  • a Group XIV protein tyrosine kinase of particular interest is FLT3.
  • the FLT3 kinase may include a mutation. There is substantial experimental and clinical evidence to support the hypothesis that FLT3 mutations are important in the initiation or maintenance of AML in some patients.
  • Activating mutations of FLT3 result in constitutive activation of FLT3 tyrosine kinase activity and can transform factor-dependent hematopoietic cells as evidenced by conversion to factor-independent growth and formation of tumours in immunodeficient mice.
  • retroviral transduction of primary murine bone marrow with an AML patient-derived FLT3 ITD (internal tandem duplication) cDNA results in a lethal myeloproliferative syndrome.
  • kinase inhibitors described herein are capable of inhibiting FLT3 including an ITD where there is a duplication of amino acids VDFREYEYDH at amino acid position 592-601.
  • the FLT3 includes an internal tandem duplication.
  • the internal tandem duplication is a duplication of amino acids VDFREYEYDH at position 592-601.
  • the inhibition of the protein kinase may be carried out in any of a number of well known ways in the art. For example if inhibition of the protein kinase in vitro is desired an appropriate amount of the compound of the invention may be added to a solution containing the kinase. In circumstances where it is desired to inhibit the activity of the kinase in a mammal the inhibition of the kinase typically involves administering the compound to a mammal containing the kinase.
  • the compounds of the invention may find a multiple number of applications in which their ability to inhibit protein kinases of the type mentioned above can be utilised.
  • the compounds may be used to inhibit protein kinases.
  • the compounds may also be used in treating or preventing a condition in a mammal in which inhibition of a protein kinase and/or co-factor thereof prevents, inhibits or ameliorates a pathology or a symptomology of the condition.
  • Examples of conditions that may be treated by inhibition of protein kinases include prostate cancer, retinoblastoma, malignant neoplasm of breast, malignant tumour of colon, endometrial hyperplasia, osteosarcoma, squamous cell carcinoma, non-small cell lung cancer, melanoma, liver cell carcinoma, malignant neoplasm of pancreas, myeloid leukemia, cervical carcinoma, fibroid tumour, adenocarcinoma of the colon, T-cell leukemia, glioma, glioblastoma, oligodendroglioma, lymphoma, ovarian cancer, restenosis, astrocytoma, bladder neoplasms, musculoskeletal neoplasms and Alzheimer's Disease.
  • Other conditions that may be treated by inhibition of protein kinases include conditions such as Myeloproliferative disorders (chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukemia), myeloid metaplasia, chronic myelomonocytic leukemia, acute lymphocytic leukemia, acute erythroblastic leukemia, Hodgkin's disease, B-cell lymphoma, acute T-cell leukemia, breast carcinoma, ovarian cancer, colon carcinoma, prostate cancer, melanoma, myelodysplastic syndromes, keloids, congestive heart failure, ischemia, thrombosis, cardiac hypertrophy, pulmonary hypertension, and retinal degeneration.
  • Myeloproliferative disorders chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukemia), myeloid metap
  • protein kinases include acute myeloid leukemia, acute promyelocyte leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, leukocytosis, juvenile myelomonocytic leukemia, acute B-cell leukemia, chronic myeloid leukemia, acute T-cell leukemia, myeloproliferative disorders, and chronic myelomonocytic leukemia.
  • the compounds of the invention may also be used the preparation of a medicament for treating a condition in an animal in which inhibition of a protein kinase can prevent, inhibit or ameliorate the pathology or symptomology of the condition.
  • the compounds of the invention may also be used in the preparation of a medicament for the treatment or prevention of a kinase-related disorder.
  • a kinase-related disorder is a proliferative disorder.
  • the proliferative disorder is elected from the group consisting of myeloproliferative disorders (chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukaemia), myeloid metaplasia, chronic myelomonocytic leukaemia, acute myeloid leukaemia, juvenile myelomonocytic leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia, acute erythroblastic leukaemia, acute B-cell leukaemia, leukocytosis, Hodgkin's disease, B-cell lymphoma, acute T-cell leukaemia, breast carcinoma, ovarian cancer, colon carcinoma, prostate cancer, melanoma, myelodysplastic syndromes, keloids, retinoblastoma,
  • the cancer may be a solid tumour.
  • the solid tumour may be a tumour present in or metastasized from an organ or tissue selected from the group consisting of breast, ovary, colon, prostate, endometrium, bone, skin, lung, liver, pancreas, cervix, brain, neural tissue, lymphatic tissue, blood vessel, bladder and muscle.
  • haematological cancers include acute myeloid leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia, myelodysplastic syndrome, leukocytosis, juvenile myelomonocytic leukaemia, acute B-cell leukaemia, chronic myeloid leukaemia, acute T- cell leukaemia, chronic myelomonocytic leukaemia, myeloid metaplasia, chronic myelomonocytic leukaemia, acute erythroblastic leukaemia, Hodgkin's disease, and B-cell lymphoma.
  • cardiovascular disorder Another kinase-related disorder is a cardiovascular disorder.
  • cardiovascular disorder include congestive heart failure, ischemia, thrombosis, cardiac hypertrophy and restenosis.
  • Another kinase-related disorder is a neurodegenerative disorder.
  • the neurodegenerative disorder may be Alzheimer's disease.
  • a kinase related disorder are inflammatory disorders and/or an autoimmune disorders.
  • disorders of this type include acute disseminated encephalomyelitis, Addison's disease, agammaglobulinemia, agranulocytosis, allergic asthma, allergic encephalomyelitis, allergic rhinitis, alopecia areata, alopecia senilis, anerythroplasia, ankylosing spondylitis, antiphospholipid antibody syndrome, aortitis syndrome, aplastic anemia, atopic dermatitis, autoimmune haemolytic anemia, autoimmune hepatitis, autoimmune oophoritis, BaIo disease, Basedow's disease, Behcet's disease, bronchial asthma, Castleman's syndrome, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, Cogans syndrome, comical cornea, comical cornea, comical cornea,
  • the inflammatory disorder is selected from the group consisting of ankylosing spondylitis, Graves' disease, inflammatory bowel diseases (Crohn's disease, ulcerative colitis), multiple sclerosis, psoriasis and rheumatoid arthritis...
  • the compounds disclosed have the ability to be used in the treatment of proliferative disorders.
  • An example of such a disorder is cancer.
  • Administration of compounds within Formula (I) to humans can be by any of the accepted modes for enteral administration such as oral or rectal, or by parenteral administration such as subcutaneous, intramuscular, intravenous and intradermal routes. Injection can be bolus or via constant or intermittent infusion.
  • the active compound is typically included in a pharmaceutically acceptable carrier or diluent and in an amount sufficient to deliver to the patient a therapeutically effective dose.
  • the inhibitor compound may be selectively toxic or more toxic to rapidly proliferating cells, e.g. cancerous tumours, than to normal cells.
  • the term 'cancer' is a general term intended to encompass the vast number of conditions that are characterised by uncontrolled abnormal growth of cells.
  • the compounds of the invention will be useful in treating various cancers including but not limited to bone cancers including Ewing's sarcoma, osteosarcoma, chondrosarcoma and the like, brain and CNS tumours including acoustic neuroma, neuroblastomas, glioma and other brain tumours, spinal cord tumours, breast cancers, colorectal cancers, advanced colorectal adenocarcinomas, endocrine cancers including adrenocortical carcinoma, pancreatic cancer, pituitary cancer, thyroid cancer, parathyroid cancer, thymus cancer, multiple endocrine neoplasma, gastrointestinal cancers including stomach cancer, oesophageal cancer, small intestine cancer, Liver cancer, extra hepatic bile duct cancer, gastrointestinal carcinoid tumour, gall bladder cancer, genitourinary cancers including testicular cancer, penile cancer, prostrate cancer, gynaecological cancers including cervical cancer,
  • Exemplary cancers that may be treated by compounds of this invention include Hematologic cancer such as myeloproliferative disorders (idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myeloid leukaemia), myeloid metaplasia, chronic myelomonocytic leukaemia, acute lymphocytic leukaemia, acute erythroblastic leukaemia, Hodgkin's and Non Hodgkin's disease, B-cell lymphoma, acute T-cell leukaemia, myelodysplastic syndromes, plasma cell disorder, hairy cell leukaemia, kaposi's sarcoma, lymphoma; gynaecologic cancer such as breast carcinoma, ovarian cancer, cervical cancer, vaginal and vulva cancer, endometrial hyperplasia; gastrointestinal tract cancer such as colorectal carcinoma, polyps, liver cancer, gastric cancer, pancreatic cancer, gall bladder cancer;
  • Exemplary cancers that may be treated by compounds of this invention include but are not limited to bladder cancer, breast cancer, cervical cancer, colorectal cancer, colon cancer, gastric cancer, neuroblastoma, retinoblastoma, ovarian cancer, pancreatic cancer, leukaemia, lymphoma, prostate cancer and lung cancer.
  • Exemplary cancers that may be treated by compounds of this invention are colon cancer, colorectal cancer, pancreatic cancer and cervical cancer.
  • cancers that may be treated by compounds of the present inventions include but are not limited to B-cell lymphoma (e.g. Burkitt's lymphoma), leukaemia (e.g. acute promyelocytic leukaemia, erythroleukemia), cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma.
  • B-cell lymphoma e.g. Burkitt's lymphoma
  • leukaemia e.g. acute promyelocytic leukaemia, erythroleukemia
  • CCL cutaneous T-cell lymphoma
  • peripheral T-cell lymphoma e.g., peripheral T-cell lymphoma.
  • the compounds of the invention will also be useful in treating various myeloproliferative disorders which may include polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis.
  • the compounds of the invention can be administered in any form or mode which makes the compound bioavailable.
  • One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the condition to be treated, the stage of the condition to be treated and other relevant circumstances. We refer the reader to Remingtons Pharmaceutical Sciences, 19 th edition, Mack Publishing Co. (1995) for further information.
  • the compounds of the present invention can be administered alone or in the form of a pharmaceutical composition in combination with a pharmaceutically acceptable carrier, diluent or excipient.
  • a pharmaceutically acceptable carrier diluent or excipient.
  • the compounds of the invention while effective themselves, are typically formulated and administered in the form of their pharmaceutically acceptable salts as these forms are typically more stable, more easily crystallised and have increased solubility.
  • compositions which are formulated depending on the desired mode of administration.
  • the present invention provides a pharmaceutical composition including a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent or excipient.
  • the compositions are prepared in manners well known in the art.
  • kits comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention.
  • a pack or kit can be found a container having a unit dosage of the agent (s).
  • the kits can include a composition comprising an effective agent either as concentrates (including lyophilized compositions), which can be diluted further prior to use or they can be provided at the concentration of use, where the vials may include one or more dosages.
  • single dosages can be provided in sterile vials so that the physician can employ the vials directly, where the vials will have the desired amount and concentration of agent(s).
  • Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • the compounds of the invention may be used or administered in combination with one or more additional drug (s) that are anti-cancer drugs and/or procedures (e.g. surgery, radiotherapy) for the treatment of the disorder/diseases mentioned.
  • additional drug s
  • the components can be administered in the same formulation or in separate formulations. If administered in separate formulations the compounds of the invention may be administered sequentially or simultaneously with the other drug(s).
  • the compounds of the invention may be used in a combination therapy. When this is done the compounds are typically administered in combination with each other. Thus one or more of the compounds of the invention may be administered either simultaneously (as a combined preparation) or sequentially in order to achieve a desired effect. This is especially desirable where the therapeutic profile of each compound is different such that the combined effect of the two drugs provides an improved therapeutic result.
  • compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
  • suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminium monostearate and gelatin.
  • the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and gly
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
  • the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
  • the active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain, inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar- agar, and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar- agar, and tragacanth, and mixtures thereof.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non- irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non- irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Dosage forms for topical administration of a compound of this invention include powders, patches, sprays, ointments and inhalants.
  • the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required.
  • the amount of compound administered will preferably treat and reduce or alleviate the condition.
  • a therapeutically effective amount can be readily determined by an attending diagnostician by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount a number of factors are to be considered including but not limited to, the species of animal, its size, age and general health, the specific condition involved, the severity of the condition, the response of the patient to treatment, the particular compound administered, the mode of administration, the bioavailability of the preparation administered, the dose regime selected, the use of other medications and other relevant circumstances.
  • a preferred dosage will be a range from about 0.01 to 300 mg per kilogram of body weight per day.
  • a more preferred dosage will be in the range from 0.1 to 100 mg per kilogram of body weight per day, more preferably from 0.2 to 80 mg per kilogram of body weight per day, even more preferably 0.2 to 50 mg per kilogram of body weight per day.
  • a suitable dose can be administered in multiple sub-doses per day.
  • the compounds of the embodiments may be useful for treating proliferative diseases.
  • cell proliferative diseases or conditions include cancer (include any metastases), psoriasis, and smooth muscle cell proliferative disorders such as restenosis.
  • inventive compounds may be particularly useful for treating tumours such as breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, head and/or neck cancer, or renal, gastric, pancreatic cancer and brain cancer as well as hematologic malignancies such as lymphoma and leukaemia.
  • inventive compounds may be useful for treating a proliferative disease that is refractory to the treatment with other anti-cancer drugs; and for treating hyperproliferative conditions such as leukemias, psoriasis and restenosis.
  • compounds of this invention can be used to treat pre-cancer conditions or hyperplasia including familial adenomatous polyposis, colonic adenomatous polyps, myeloid dysplasia, endometrial dysplasia, endometrial hyperplasia with atypia, cervical dysplasia, vaginal intraepithelial neoplasia, benign prostatic hyperplasia, papillomas of the larynx, actinic and solar keratosis, seborrheic keratosis and keratoacanthoma.
  • the agents of the various embodiments may be prepared using the reaction routes and synthesis schemes as described below, employing the techniques available in the art using starting materials that are readily available.
  • the preparation of particular compounds of the embodiments is described in detail in the following examples, but the artisan will recognize that the chemical reactions described may be readily adapted to prepare a number of other agents of the various embodiments.
  • the synthesis of non-exemplified compounds may be successfully performed by modifications apparent to those skilled in the art, e.g. by appropriately protecting interfering groups, by changing to other suitable reagents known in the art, or by making routine modifications of reaction conditions.
  • a list of suitable protecting groups in organic synthesis can be found in T. W. Greene's Protective Groups in Organic Synthesis, 3 rd , John Wiley & Sons, 1991.
  • other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the various embodiments.
  • Reagents useful for synthesizing compounds may be obtained or prepared according to techniques known in the art.
  • THF Tetrahydrofuran
  • DMF N 1 N- dimethylformamide
  • the reactions set forth below were performed under a positive pressure of nitrogen, argon or with a drying tube, at ambient temperature (unless otherwise stated), in anhydrous solvents, and the reaction flasks are fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven-dried and/or heat-dried. Analytical thin-layer chromatography was performed on glass-backed silica gel 60 F 254 plates (E Merck (0.25 mm)) and eluted with the appropriate solvent ratios (v/v). The reactions were assayed by TLC and terminated as judged by the consumption of starting material.
  • the TLC plates were visualized by UV absorption or with a p-anisaldehyde spray reagent or a phosphomolybdic acid reagent (Aldrich Chemical, 20 wt% in ethanol) which was activated with heat, or by staining in an iodine chamber. Work-ups were typically done by doubling the reaction volume with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25% by volume of the extraction volume (unless otherwise indicated). Product solutions were dried over anhydrous sodium sulfate prior to filtration, and evaporation of the solvents was under reduced pressure on a rotary evaporator and noted as solvents removed in vacuo. Flash column chromatography [Still et al, J.
  • CDCI 3 solutions (reported in ppm), using chloroform as the reference standard (7.27 ppm and 77.00 ppm) or CD 3 OD (3.4 and 4.8 ppm and 49.3 ppm), or an internal tetramethylsilane standard (0.00 ppm) when appropriate.
  • Other NMR solvents were used as needed.
  • Mass spectra were obtained using LC/MS either in ESI or APCI. All melting points are uncorrected.
  • Scheme 1 is a general synthetic scheme outlining the procedure for the preparation of compounds of general formula (VIII).
  • Step 2 2-[(2-Dimethylamino-ethyl)-methyl-amino]-5-nitro-phenyl ⁇ -methanol
  • Step 3 ⁇ /-(2-Allyloxymethyl-4-nitro-phenyl)-/V, ⁇ /', ⁇ /'-trimethyl-ethane-1,2-diamine
  • In vitro kinase activity assay The recombinant enzymes (CDK2/CyclinA, FLT3, JAK2 and JAK2 V617F) were purchased from Invitrogen (Cat # PV3267, 3182, 4210 and 4347 respectively). All assays were carried out in 384-well white microtiter plates using the PKLight assay system from Cambrex (East Rutherford, New Jersey). This assay platform is essentially a luminometric assay for the detection of ATP in the reaction using a luciferase-coupled reaction.
  • the reaction mixture consisted of the following components in 25 ⁇ l_ assay buffer (50 mM Hepes pH 7.5, 10 mM MgCI 2 , 5 mM MnCI 2 , 5 mM BGP 1 1 mM DTT, 0.1 mM sodium orthovanadate), 1.4 ⁇ g/mL of CDK2/Cyclin A complex, 0.5 ⁇ M of RbING substrate (Invitrogen, Cat # PV2939) and 0.5 ⁇ M of ATP. The compounds were tested at 8 concentrations prepared from 4-fold serial dilution starting at 10 ⁇ M. The reaction was incubated at room temperature for 2 hr.
  • PKLight ATP detection reagent 13 ⁇ L was diluted in PKLight ATP detection reagent incubated for 10 min. Luminescence signals were detected on a multi-label plate reader (Victor 2 V 1420, Perkin-Elmer). The other kinase assays were identical except for the following differences in reagents.
  • the reaction contained 2.0 ⁇ g/mL FLT3 enzyme, 5 ⁇ M of poly(Glu.Tyr) substrate (Sigma, Cat # P0275) and 4 ⁇ M of ATP.
  • the reaction contained 0.6 ⁇ g/mL of JAK2 enzyme, 2 ⁇ M of poly(Glu,Ala,Tyr) substrate (Sigma, Cat # P3899) and 0.2 ⁇ M of ATP.
  • the reaction contained 8.0 ⁇ g/mL of JAK2 mutant enzyme, 2 ⁇ M of poly(Glu,Ala,Tyr) substrate (Sigma, Cat # P3899) and 0.2 ⁇ M of ATP.
  • the analytical software, Prism 4.0 GraphPad Software Pte Ltd was used to generate IC 50 values from the data.
  • IC 50 is defined as the concentration of compound required for 50% inhibition of kinase enzyme activity.
  • ClogP and TPSA were calculated using MOE V2006.08: which is available from Chemical Computing Group Suite 910 - 1010 Sherbrooke St. WMontreal, Quebec, Canada H3A 2R7.
  • ClogD was calculated using Pallas PrologD v2.01: which is available from CompuDrug International, Inc., 115 Morgan Drive, Sedona, AZ 86351 , USA.
  • the pyridyl compound shows marked improvement in comparison to the phenylene derivatives.
  • the pyridyl compound shows improved JAK2 activity and is also a potent inhibitor of CDK2.
  • CLogP and CLogD of the pyridyl compounds are also improved indicating the improved drug like properties of this molecule.
  • the pyridyl compound shows marked improvement in comparison to the phenylene derivatives. Whilst having comparable JAK2 activity the pyridyl compound has remarkably improved CDK2 activity. In addition CLogP and CLogD of the pyridyl compound is also improved indicating the improved drug like properties of this molecule.
  • CLogP and CLogD of the pyridyl compound is also improved indicating the improved drug like properties of this molecule.
  • the pyridyl compounds of the invention show excellent CDK2 activity and in general have improved drug like properties when compared to the phenylene moieties.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur des composés de pyrimidine à substitution pyridyle qui sont utiles en tant qu'agents pour le traitement de troubles liés à la kinase, tels que des troubles prolifératifs. Plus particulièrement, la présente invention porte sur des composés de pyrimidine liés à l'oxygène et à substitution pyridyle, sur des procédés pour leur préparation, sur des compositions pharmaceutiques contenant ces composés et sur des utilisations de ces composés dans le traitement de troubles prolifératifs. Ces composés peuvent être utiles en tant que médicaments pour le traitement d'un certain nombre de troubles liés à la kinase, tels que des troubles prolifératifs comprenant les tumeurs et les cancers ainsi que d'autres troubles ou états liés ou associés aux kinases.
PCT/SG2008/000178 2007-05-15 2008-05-14 Dérivés de pyrimidine à substitution pyridyle WO2008140419A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92444407P 2007-05-15 2007-05-15
US60/924,444 2007-05-15

Publications (2)

Publication Number Publication Date
WO2008140419A2 true WO2008140419A2 (fr) 2008-11-20
WO2008140419A3 WO2008140419A3 (fr) 2009-04-30

Family

ID=40002772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2008/000178 WO2008140419A2 (fr) 2007-05-15 2008-05-14 Dérivés de pyrimidine à substitution pyridyle

Country Status (1)

Country Link
WO (1) WO2008140419A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8235986B2 (en) 2007-10-05 2012-08-07 Coaptus Medical Corporation Systems and methods for transeptal cardiac procedures, including tissue penetrating members and associated methods
WO2021219731A2 (fr) 2020-04-28 2021-11-04 Iomx Therapeutics Ag Inhibiteurs de kinase bicycliques et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078682A2 (fr) * 2003-03-05 2004-09-16 Irm Llc Composes cycliques et compositions servant d'inhibiteurs de proteines-kinases
WO2007058627A1 (fr) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Derives de pyrimidine a liaison oxygene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078682A2 (fr) * 2003-03-05 2004-09-16 Irm Llc Composes cycliques et compositions servant d'inhibiteurs de proteines-kinases
WO2007058627A1 (fr) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Derives de pyrimidine a liaison oxygene

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8235986B2 (en) 2007-10-05 2012-08-07 Coaptus Medical Corporation Systems and methods for transeptal cardiac procedures, including tissue penetrating members and associated methods
WO2021219731A2 (fr) 2020-04-28 2021-11-04 Iomx Therapeutics Ag Inhibiteurs de kinase bicycliques et leurs utilisations

Also Published As

Publication number Publication date
WO2008140419A3 (fr) 2009-04-30

Similar Documents

Publication Publication Date Title
US8143255B2 (en) Heteroalkyl linked pyrimidine derivatives
WO2008060248A1 (fr) Pyrimidines substituées par indole, et leur utilisation dans le traitement d'un cancer
WO2008140420A2 (fr) Dérivés de pyrimidine
US20220241291A1 (en) Oxygen linked pyrimidine derivatives
WO2008140419A2 (fr) Dérivés de pyrimidine à substitution pyridyle
WO2008140421A2 (fr) Dérivés de pyrimidine à substitution hétérocycloalkyle
EP1951730B1 (fr) Derives de pyrimidine a liaison heteroalkyle
MX2008006431A (en) Heteroalkyl linked pyrimidine derivatives
MX2008006432A (en) Oxygen linked pyrimidine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08754016

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08754016

Country of ref document: EP

Kind code of ref document: A2